Abstract: Toll-like receptor (TLR) agonists induce potent innate immune responses and can be used in the development of novel vaCCine adjuvants. However, access to TLAs can be challenging as exemplified by TLR 7, which Is located intracellularty in endosomal compartments. To increase recognition and subsequent stimulatory effects of TLR 7, imiquimod was encapsulated in acetalated dextran (Ac-DEX) micropartlcles. Ac-DEX, a water-insoluble and blocompatible potymer,ls relatiVely stable at pH 7.4, but degrades rapidly under acidic conditions, such as those found in lysosomal vesicles. To determine the immunostimulatory capacity of encapsulated imiquimod, we compared the efficacy of free versus encapsulated imiquimod in actiVating RAW 264 .. 7 macrophages, MH·S macrophages, and bone marrow derived dendritic cells. Encapsulated imiquimod significantly increased IL-1/1, IL-6, and TNF-u cytokine expression in macrophages relative to the free drug. Furthermore, significant increases were observed in classic macrophage activation markers (iNOS, PD1 ~ 1, and NO) after treatment with encapsulated imiquimod over the free drug, Also, bone marrow derived dendritic cells produced significantly higher levels of IL-1{3. IL-6; ll-12p70, and M!P-1u as compared to their counterparts receiving free imiquimod. These results suggest that encapsulation of TLA ligands within Ac-DEX microparticles results In increased immunostimulation and potentially better protection from disease when used in conjunction with.vaccine formulations.
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ABSTRACT
Toll-like receptor (TLR) agonists induce potent innate immune responses and can be used in the development of novel vaCCine adjuvants. However, access to TLRs can be challenging as exemplified by TLR 7, which Is located intracellularty in endosomal compartments. To increase recognition and subsequent stimulatory effects of TLR 7, imiquimod was encapsulated in acetalated dextran (Ac-DEX) micropartlcles. Ac-DEX, a water-insoluble and blocompatible potymer,ls relatiVely stable at pH 7.4, but degrades rapidly under acidic conditions such as those found in lysosomal vesicles. To determine the immunostimulatory capacity of encapsulated imiquimod, we compared the efficacy of free versus encapsulated imiquimod in actiVating RAW 264 .. 7 macrophages, MH?S macrophages, and bone marrow derived dendritic cells. Encapsulated imiquimod significantly increased IL-1/1, IL-6, and TNF-u cytokine expression in macrophages relative to the free drug. Furthermore, significant increases were observed in classic macrophage activation markers (iNOS, PD1 ~ 1, and NO) after treatment with encapsulated imiquimod over the free drug, Also, bone marrow derived dendritic cells produced significantly higher levels of IL-1{3. IL-6; ll-12p70, and M!P-1u as compared to their counterparts receiving free imiquimod. These results suggest that encapsulation of TLR ligands within AcDEX microparticles results In increased immunostimulation and potentially better protection from disease when used in conjunction with.vaccine formulations.
SUBJECT TERMS
SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT
Activation of an innate immune response occurs by stimulation of pattern recognition receptors (PRR). such as tolllike receptors (TLRs) 1md the more recently identified NODlike receptors (NLRs).
•
8 PRRs are highly conserved structures among an array of species that activate after binding of pathogen associated molecular patterns (PAMPs) such as lipopolysacharride (LPS) and unmethylated CpG DNA. The binding of PAMPs to TLRs results in significant immune activation characterized by dendritic cell maturation, inflammatory cytokine production, trafficking of dendritic cells to secondary lymphoid tissue, and activation of adaptive immune responses through interactions with naive T cells.
7
This mechanism allows TLR agonists to drastically increase the potency of subunit vaccines.
Imidazoquinolines (imiquimod or resiquimod) are synthetic, FDA approved, immunostimulants that have recently been successful in improving the efficacy of subunit Y1lC-cines.9 Traditionally, imidazoquinolines have been used for the treatment of several ailments including genital warts, w actinic keratosis, 
• 18
Stimulation of TLR 7 or TLR 8 induces the activation of the MyD88 signaling cascade, 18 ultimately resulting in the production of the inflammatory cytokines lL-1/J, IL-6, TNFa, and IFN-a. 7 The activity of these compounds has been attributed to their ability to stimulate antibody and T cell mediated responses as well as inducing significant inflammatory cytokine production when topically administered.
19
·;w
Despite the successful use of this molecule in the treatment of several illnesses, it is not without limitations. In particular, imiquimod is a poorly soluble compound limiting parenteral adminisu·ation in vivoY In addition, when delivered systemically, imiquimod initiates a cascade of inflammatory cytokines and pro-apoptotic factors that prove detrimental to the host. 22 For this reason, deli very of imiquimod is restricted to topical administration, which limits the range of ailments to which it may be applied. In this study, we investigated the potential of using Ac-DEX microparticles as a delivery system for imiquimod induced stimulation. Encapsulated imiquimod was delivered to macrophages and dendritic cells and assayed for inft:unmatory cytokine production and a,~tivation. He.rein, we find that Ac-DEX particles are an ideal delivery vehicle for the encapsulation and delivery of imiquimod to macrophage& and dendritic cells,
Materials and Methods
Cell Lines and Bone Marrow Derived Cells. MH-S and RAW 264.7 macrophages were porchased from ATCC (Manassas, VA). Cells were grown and maintained as per guidelines provided by the manufacturer. Bone marrow derived dendritic cells were prepared as previously dest:ribed.n Briefly, bone marrow was harvested from 6-8 week old A/J mice and treated with 3 ng/mL each of IL-4 and GM-CSF for 5 days. Cells were harvested after 5 days and sorted L'ia magnetic bead isolation for CD 1 1 c expression.
The experiments reported herein were conducted in compliance with the Animal Welfare Act and in accordance with the principles set forth in the Guille jllr the Care mul Use of Laboratory Animals, Institute of Laboratory Animals Resources, National Research Council, National Academy Press, l996.
General 1\:laterials and Methods. All reagents were purchased from commercial sources and used with(JUt further purification. Water (dd-H 2 0) for buffers and particle washing steps was purified to a resistance of 18 MQ using a NANOpure purification system (Barnstead). When used in the presence of acetal-\~ontaining materials. dd-H 2 0 was rendered basic (pH 9) by the addition of triethylamine (TEA Prepar..tion of Single Emulsion Particles Encapsulating Imiquimod. Microparticles containing imiquirnod were prepared using an oil-in-water emulsion method similar to the technique described by Bachelder et al.
38 lmiquimod (SigmaAldrich) (4 mg) was dissolved in chloroform (2 mLJ by heating the imiquimod/chloroform solution for l5 min at 50 "C, The solution was allowed to cool to room temperature, and then used to dissolve Ac-DEX ( 100 mg), The resulting solution was added to an aqueous solution of poly(vinyl alcohol) (PVA, MW 13.000-23,000 glmol, 87-89% hydrolyzed) (2 mL, 3% w/w in PBS) aud sonicated for 30 s on ice using a probe sonicator (Branson Sonifier 450, with a 0.5 in. flat tip) with an output setting of 3 and a duty cycle of IO%. The resulting single emulsion was immediately poured into a second PV A solution 0 0 mL, 0.3% wlw in PBS) and stirred for 4 h to allow the organic sol vent to evaporate. The particles were isolated by centrifugation (14800g, 15 min. 4 °C) and washed with dd-H 2 0 l3 x 50 mL, pH 9). The washed particles were resuspended in dd-H20 (2 mL, pH 9) and lyophilized to yield a white fluffy solid (87 mg).
Preparation of Empty Single Emulsion Particles. Empty Ac-DEX particles were made in the same manner as above omitting imiquimod.
Quantification of Encapsulated lmiquimod. Particles (1 mg) were dissolved in DMSO (I mL) and analyzed for imiquimod content by measuring fluorescence using a Spectra Max Gemini XS microplate reader (Molecular Devices, Sunnyvale, CA) (ex, 325 nm, em. 365 nm), The results were compared to a standard curve. and the mass of inliquimod was calculated. Tl1e imiquimod loading was found to be 4.1 ± 0.2 wt %, and the loading efficiency was essentially quantitative.
Scanning Electron Microscopy. Mkroparticles were characu.~rized by scanning electron microscopy using an S-5000 microscope (Hitachi, Japan). Particles were suspended in dd-~ (pH 9) at a concentration of l mg/mL, and the resulting dispersions were dripped onto a silicon wafer. After 15 min. the remaining water was wicked away using tissue paper and the samples were allowed to air-dry. The particles were then sputter coated with a 2 nm layer of a palladium/gold alloy and imaged.
Release Profile of bniquimod. 4 mg of particles (in triplicate per pH} was suspended in either l mL of PBS (pH 7A) or 0,3 M acetate buffer (pH 5.0). The particle suspensions were then injected into a presoaked Slide·A-Lyzer cassette per the manufacturer's instructions (Thenno Scientific, Waltham, MA), The Slide-A-Ly:zer cassette was placed in 800 mL of buffer at 37 "C and stirred moderately. Samples Particle Size Analysis by Dynamic Light Scattering.
Particle size distributions were determined by dynamic light scattering using a Zetasizer Nano ZS (Malvern Instruments, U.K.). Particles were suspended in dd-H 2 0 (pH 9) at a concentration of I mglmL, and three measurements were taken of the resulting dispersions. The results in the text are presented as average particle diameters ± width of the distribution at half maximal height.
In Vitro Toxicity. To assess of the relative toxicity of Ac-DEX micmpartides, MH-S and RAW 264.7 macrophages were plated atl x 10" cefls/mL and incubated overnight in RPl\fi medium 1640/10% FBS/1% penicillin~streptomycin. The medium in each well was replaced by I 00 pL of new medium containing either empty Ac-DEX particles, imiquimod encapsulated in Ac-DEX particles or free imiquimod, ranging from 0.25 pglmL to 4 mg/mL. Assays were conducted in replicates of three for each concentr:uion. After incubation tor 20 h; a 40 pL solution of MTT solution (2.91 mg/mL) was added to each well. The cells were incubated for 3 h. after which time the medium was carefully removed. DMSO (200 pL) was added to the resulting purple crystals tollowed by a glycine buffer (25 pL, pH IO, 0.1 M glycine, OJ M NaCI). The optical densities at 570 um were measured using a Spcctr:u\1AX J 90 microplate reader (Molecular Devices, Sunnyvale. CA).
Nitrite Analysis. Briefly. the concentration of nitrite in supernatants of RAW 264.7 and MH-S alveolar macrophages was determined spectrophotometrically using the Griess reagent. Macrophages were plated at 5 x 10 5 cells/mi... in 24-well plates and left overnight to adhere. Cells were treated with serial dilutions of medium, free irniquimod, imiquirnod encapsulated in Ac-DEX particles. or empty particles for 24 h. Supernatants were collected after24h, mixed Ill with Gliess reagent, and absorbances were measured at 543 nm u~ing a SpectraMax 360 microplate reader (Molecular Devices. Sunnyvale, CA). The nitrite concentration was determined using sodium nitrite as a standard.
RNA Isolation and Purification and Real Time Polymerase Chain Reaction. MH-S alveolar macrophages
and RAW 264.7 macrophages were plated in 24-well plates overnight at 5 x I<P cells/mL and treated the next day with medium, free imiquimod, imiquimod encapsulated in Ac-DEX part1des. or empty particles for 6 h. Cells were lysed with Buffer RL T (Qiagen Sciences, Valencia, CA). containing 2-f)-mercaptoethanol, and spun through Qiashredder tubes (Qiagen Sciences, Valencia, CA). Total RNA was extracted using the RNeasy Mini Kit (Qiagen Sciences. Valencia, CA). Individual sample RNA (0.1 Jtg) was reverse-transcribed using Superscript U (Invitrogen, Carlsbad. CA) and a mixture of oligo (dT) a11d random primers. Real-time polymerase chain reaction (RT·PCR) was performed on an ABI Prism 7900HT sequence detection system (Applied Biosystems. Foster City, CA). Sequences for hypoxanthine guanine 830 MOLECULAR PHARMACEUTICS VOL 7, NO. 3
Bachelder n a!. CTGTTGTTCCTCA TTG reverse-TCCACA TCTAGCAT-TCTCACTTG. Relative quantities of mRNA for several genes was determined using SYBR Green PCR Ma!iter .Mix {Applied Biosystems, Foster City, CA) and by the comparative threshold cyde method as described by Applied Biosystems for the ABI Prism 7900HT sequence detection systems. In this method, mRNA levels for each sample were nommlized to HPRT mRNA levels and then expressed as a relative increase or decrease compared with levels in untreated controls.
Multiplex-Bead Analyst~ MH-S alveolar macrophages and RAW 264.7 macrophages were plated in 24-well plates overnight at 5 x l<P cells/mL. and treated the next day with medium, free imiquimod. imiquimod encapsulated in Ac-DEX particles, or empty particles for 24 h. Cytokine production was assayed from supernatants of cells treated with various concentrations of imiquimod (0.5 ftg/mL to .:t pg/mL). Eight cytokineslchemokines were assayed using a mouse multiplex assay system (BioRad, Hercules, CA): ILljJ, lL-2, lL-6, IL-l2p70, lFN-y, TNF-o., and MlP-lo.. Samples were run individually. but replicated in mulliple experiments. Individual standards provided by the manufacturer were run on each plate. Data was collected using a BioRadLuminex-200 system, and analyzed using the BioRad Bio-Plex Manager Software (version 4.1).
Statistics. Differences in cytokine, mRNA expression. nitrite, and protein levels were evaluated by ANOV A.
Differences were considered significant when p < 0.05*, p < 0.01 **,or p • 0.001 ***.
Results and Discussion
Ac·DEX Microparticles Exhibit Low Toxicity in Vitro. Under acidic conditions, the pendant acetals on Ac-DEX hydrolyze to yield the parent water-soluble polymer, dextran (Figure l A) .' 6 Microparticles >vere fabricated from Ac-DEX using a standard emulsion technique and appeared as shown in the SEM micrograph in Figure lB . The irniquimod loading of the particles was 4 wt %. and the loading efficiency was 100%. This loading efficiency is substantially higher compared to what can be obtained using To asses the biocompatibility of Ac-DEX micropartides, viability assays were perf01med with APCs. As shown in Figure  ID , empty Ac-DEX microparticles (0.25 ,ug/mL to 4 mg/mL) had little effect on the viability ofbolh MH-S and RAW 264.7 maerophagcs, suggesting the particles were well tolerated even at high concentrations. Due to their pH-sensitive degradation properties, appropriate size, and neg. ligible toxicity, Ac-DEX microparticles are a promising delivery platform for adjuvants and immunostimulatory ligands. 
69-76.
The pH sensitivity of the particles was tested by incubating inuquimod encapsulated in Ac-DEX in either a pH 5.0 or pH 7.4 buffer and measuring the release of imiquimod at the designated times (Figure 1 E) . At pH 5Ji the Ac-DEX particles quickly released the encapsulated imiquimod. This quick release should be beneficial for lhe activation of dendritic cells; upon internalization, Ac-DEX particles exposed to the low pH environment present in lysosomal compartments, release a bolu.~ of imiquimod irt'proximity to TLR7/8. At pH 7.4 Ac-DEX microparticles releasL-d approximately 20% of the encapsulated drug within 48 h, after which time the release rate lev~led off. This initial burst release .is very common with the encapsulation of drugs using single emulsion encapsulation techniques.
.4~~
With the use of Ac-DEX particles we could potentially dex. :rease the amount of im.iquimod used as an adjuvant in a potential vaccine application. Future experiments will be done to decrease the initial burst release of imiquimod in our microparticle carriCl' system. . . .
.·Encapsulated lmiquimod • Empty Particle Figure 2 . Encapsulation of imiquimod in Ac-DEX microparticles results in significantly higher inflammatory cytokine production in vitro. (A and B) 5 x 10 6 cellslml MH-S and RAW 264.7 macmphages (N = 3) were stimulated for 6 h with medium, free imiquimod, encapsulated imiquimod, or empty particles, and prepared individually for real-time PCR analysis for IL·1/J. IL-6, and TNF-a expression. Gene expression (mean ± SEM) is expressed as the fold increase over medium controls after normalization to HPRT. In separate experiments 1 x 10 6 cells/ml RAW 264.7 and MH·S (N = 3) were stimulated with medium, free imiquimod, encapsulated imiquimod, or empty particles. After 24 h the supernatants were removed and assayed for protein concentration of IL-1/J, IL-6, and TNF-a via Luminex. Graphs are representative of at least two individual experiments.
•p < 0.05, •• p < 0.01, *'*p < 0.001.
during innate responses and antigen presenting cells during adaptive immune responses. FUI1hennore, alveolar macrophages provide a critical first line of protection during pulmonary exposure to pathogens, and due to the ability of Ac-DEX microparticles to potentially be delivered either as an aerosol or as an injection, it is important to evaluate immune responses induced by various types of macrophages. Therefore, we chose to examine the activity of imiquimodloadcd Ac-DEX particles in both MH-S alveolar macrophages and RAW 264.7 macrophages.
MOLECULAR PHARMACEUTICS VOL. 7, NO_ 3
We hypothesized that the encapsulation of imiquimod in Ac-DEX microparticles would result in higher inflammatory cytokine production by macrophages because Ac-DEX particles are stable at physiological pH. and can release a bolus of imiquimod following internalization by APCs. We reasoned that endoc:rtosis of the microparticles by macrophages, and eventual degradation of the particle in the low pH environment within phagolysosomes, would efficiently deliver imiquimod at a higher concentration than free imiquimod, resulting in higher TLR 7/8 activation. To explore our Gene expression (mean ± SEM) is expressed as the fold increase over medium controls after normalization to hypoxanthine guanine phosphoribosyl transferase HPRT. (8) 1 x 1 0 6 /ml RAW 264.7 and MH-S (N = 3) were stimulated with medium, free imiquimod, encapsulated imiquimod, or empty particles. After 24 h, the supernatants were removed and the presence of nitrite was quantified by the Griess assay. Graphs are representative of at least two individual experiments.
•p < 0.05, **p < 0.01, ***p < 0.001.
hypothesis, we assayed gene expression levels and protein concentrations of the inflammatory cytokines IL-lfJ, IL-6, and TNF-o. in both macrophage cell lines after treatment with several concentrations of free or encapsulated imiquimod. MH-S macrophages demonstrated significantly increased gene expression for IL-lfJ, JL-6, and TNF-o. at multiple dosages, with greater differences observed at the lowest concentrations (1 ,ttg/mL and 0.5 ,ttg/mL) for all three cytokines (p < 0.001 for all cytokines and dosages with the exception of TNF-o. at l ,ug/mL with a p < 0.05) ( Figure  2A) . Similarly, protein production of IL-6 and TNF-o. in MH-S macrophages exposed to encapsulated imiquirnod was much higher compared to free imiquimod at lower concentrations. Interestingly, both free imiquimod and encapsulated imiquimod were capable of boosting IL-IfJ ttanscript and protein levels above baseline production in MH-S macrophages, which are known to constitutively secrete this cytokineJ4 ( Figure 2A ). Protein concentrations of IL-lfJ were similar for both free and encapsulated imiquimod at doses greater than J ,ug/mL, A difference was observed at the lowest concentration, where only encapsulated imiquimod was able to mainta.in elevated production. Similarly, lL-lfJ was upregulated in RAW 264.7 macrophages at both the transcript and protein leveL Significant differences in IL-lfJ protein production were observed at the lowest concentrations of encapsulated imiquimod (p < 0.01 for I ,ug/mL and p < 0.001 for 0.5 pg/mL dosages) ( Figure 2B ). Notably. MH-S and RAW 264.7 macrophages treated with empty particles induced little to no production of cytokines at either the transcript or protein level. Furthermore, similar patterns were observed in measurements of lL-6 and TNF-o. in both cell lines consistent!o with the conct.'Pt that encapsulation of imiquimod provides significantly more efficient delivery of the TLR ligand. Overall, imiquimod encapsulated in Ac-DEX particles induced production of a relatively high amount of IL-l fl. IL-6, and TNF-u at lower concemrations compared to free imiquimod. Based on this data. we predict that the encapsulation of imiquimod will allow dose spru.ing when performing treatments in vivo.
We also assessed the level of macrophage activation by examining the production of classical activation markers, including PDl-Ll, iNOS. and the downstream product of iNOS activity, nitric oxide. Prior research h.a.~ shown that nitric oxide production in macrophages is crucial for clearance of intracellular bacteria:~5 As shown in Figure 3A , encapsulation of imiquimod resulted in significantly higher iNOS expression (p < 0.001 for all dosages). compared to free imiquimod, when tested in both MH-S and RAW 264.7 macrophages.ln addition, as shown in Figure 3B , nitric oxide (NO) production was significantly upregulated in encapsulated versus free imiquimod (p < 0.001) at all concentrations in both MH-S and RAW 264.7 macrophages after 24 h. Jmiquimod encapsulated in Ac-Dex particles led to sirnificantly higher levels ofPDI-Ll than free imiquimod in MH-S macrophages at the three lowest concentrations (minimum of p < 0.01 for all dosages). while RAW 264.7 macrophages yielded significantly higher PDI-Ll expression at the three highest concentrations (p < 0.001 ).
Examination of these two markers suggests that imiquimod is capable of inducing macrophage activation on its own, but that this activation can be significantly augmented by the encapsulation of the TLR7/8 ligand in an acid-sensitive vehicle. Furthermore. when we measured the responses for these markers with cells that had been treated with empty particles, we observed no significant increases in any of the Cyiokines or macrophage activation markers. These data suggest that these particles are not stimulatory on their own. and that the changes in activation status are due to their ability to deliver an immunostimulatory payload. Taken together, this data clearly indicates that the encapsulation of imiquimod in Ac-DEX particles leads to significantly increased cytokine production by macrophages in vitro.
Encapsulation of Imiquimod Significantly Increases Cytokine and Chemokine Production in Bone Marrow
Derived Dendritic Cells. While macrophagcs are capable of antigen presentation, they are most typically noted for their effector abilities. ln contrast, myeloid dendritic cells are widely considered to be professional antigen presenting cells. and as such, we wanted to assess the ability of Ac-DEX particles to effectively deliver immunostimulatory ligands to this cell type. Therefore. bone marrow derived dendritic cells (BMDCs) were used to assess the activitv of imiquimod encapsulated in Ac-DEX particles. Irniqui~10d concentrations were similar to those analyzed in previous experiments (i.e .• serial dilutions from 4 Jtg/mL to 0.5 11g! mL). Supernatants from cell cultures were harvested and assayed for the production of protein using a multiplexed bead assay. As shown in Figure 4 , BMDCs exposed to encapsulated irniquimod yielded significantly higher levels of IL-1/J and JL-6 at the two highest concentrations (p < 0.001 ), as compared to similar amounts of free imiquimod. Similarly. we observed significant increases in the amounts ofiL-J2p70 (p < 0.01 or greater for all dosages) and MlPla (p < 0.001 for 4 pg/mL and 2 ,uglmL dosages) in encapsulated imiquimod groups as opposed to nonencapsulated groups.
Previous work has shown that dendritic cells treated with free imiquimod will produce the inflammatory cytokines IL-1/3 and IL-6 and IL-12p70. 46 To the best of our knowledge 
Figure 4. Microencapsulation of imiquimod using Ac-DEX microspheres results in higher BMDC activation. BMDCs (N = 3) were stimulated for 24 h with medium, free imiquimod, encapsulated imiquimod, or empty particles. Supernatants were collected assayed for protein concentration of IL-1/J, IL-6, 1L-12p70, and MIP-1o. using a multiplexed assay. Graphs are representative of at least two individual experiments. "'p < 0.01, ~"'*p < 0.001.
this is the first published report showing that encapsulated imiquimod drastically increases the production of inflammatory cytokines in dendritic cells and macrophages compared to free imiquimod. As stated previously. the incorporation of imiquimod is relatively easy compared to the methods required to encapsulate other adjuvants such as CpG and poly (l:C). The efficacy of encapsulating imiquimod is illustrated by the upregulatiou of IL-12p70 in encapsulated imiquimod treated DCs. IL-12p70 upregulation is beneficial in initiating an immune response since it is known to induce IFN-y production from NK and NKT cells, and induces the differentiation oi Th 1 cells.-' 7 In addition, the increase in the production of MIP-la by dendritic cells treated with encapsulated irniquimod suggests an enhanced ability to attract T cells and subsequently establishing a cytotoxic or adaptive immune response. Taken together, these results indicate that the encapsulation of imiquimod in acid-sensitive microparticles leads to enhanced TLR 7/8 signaling, results in a greater effect on dendritic cell activation and has the potential to drastically enhance the efficacy of in rivo vaccine applications. Prior work has shown that the imidaz.oquinoline 3M-Ol9. when encapsulated in a liposome. will increase the production of antibodies compared to the free imidazoquino- 
Conclusions
The implications of our results are broad in their ap· plicability. First,. we have shown that encapsulation of the FDA approved imiquimod in acid-degradable particles can significantly enhance the in vitro activation of macrophages and dendritic cells at levels which exceed treatment with free imiquimod alone. These data set the stage for targeted articles codelivery of vaccine constructs along with a potent adjuvant to inrracellular compartments. rhus reducing the amount of vaccine and adjuvant necessary to induce protection. St-'COnd, we have illustrated !.hat dose sparing occurs with the encapsulation of imiquimod. Through encapsulation, we can reduce the amount of imiquimod required and potentially alleviate side effects associated with its use. Third, the methods required to encapsulate imiquimod are relatively easy compared to the methods required to encapsulate other adjuvants. Based on the ability of Ac-DEX mii.'Toparticles tO effectively deliver imiquimod to macrophages and dendritic cells in vitro, we feel this is a successful platform that can be partnered with DNA and protein based vaccine candidates for future in vivo testing.
